1MINI E,NOBILI S,CACIAGLI B,et al.Cellular pharmacology of g emcitabine[J].Ann Oncol,2006,17(5):7-12.
2P(E)REZ TORRAS S,GARCA MANTEIGA J,MERCAD(E) E,et al.Adenoviral-mediated overexpression of human equilibrative nucleoside transporter 1(hENT1)enhances gemcitabine response in human pancreatic cancer[J].Biochem Pharmacol,2008,76(3):322-329.
3OGURI T,ACHIWA H,MURAMATSU H,et al.The absence of human equilibrative nucleoside transporter 1 expression predicts nonresponse to gemcitabine-containing chemotherapy in non-small cell lung cancer[J].Cancer Lett,2007,256(1):112-119.
4COSTANZI S,VINCENZETTI S,CRISTALLI G,et al.Human cytidine deaminase:A three-dimensional homology model of a tetrameric metallo-enzyme inferred from the crystal structure of a distantly related dimeric homologue[J].Mol Graph Model,2006,25(1):10-16.
5TIBALDI C,GIOVANNETTI E,VASILE E,et al.Correlation of CDA,ERCC1,and XPD polymorphisms with response and survival ingemcitabine/cisplatin-treated advanced non-small cell lung cancer patients[J].Clin Cancer Res,2008,14(6):1797-1803.
6WATANABE S I,UCHIDA T.Expression of cytidine deaminase in human solid tumors and its regulation by 1α,25-dihydroxyvitamin D3[J].Biochim Biophys Acta,1996,1312(2):99-104.
7OQAWA M,HORI H,OHTA T,et al.Sensitivity to gemcitabine and its metabolizing enzymes in neuroblastoma[J].Clin Cancer Res,2005,11(9):3485-3493.
8SEBASTIANI V,RICCI F,RUBIO VIQUIERA B,et al.Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer:relationship to molecular mechanisms of gemcitabine resistance and survival[J].Clin Cancer Res,2006,12(8):2492-2497.
9OHHASHI S,OHUCHIDA K,MIZUMOTO K,et al.Down-regulation of deoxycytidine kinase enhances acquired resistance togemcitabine in pancreatic cancer[J].Anticancer Res,2008,28(4B):2205-2212.
1Gautam A, Li Z R, Bepler G. RRM1-induced metastasis suppression through PTEN-regulated pathways[J]. Oncogene, 2003, 22(14): 2135-2142.
2Bepler G, Sharma S, Cantor A, et al. RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancer[J]. J Clin Oncol, 2004, 22(10): 1878-1885.
3Rosell R, Taron M, O' Brate A. Predictive molecular markers in non-small-cell lung cancer[J]. Curt Opin Oncol, 2001, 13(2): 101-109.
4Goan Y G, Zhou B, Hu E, et al. Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2-difluorodeoxycytidine in the human KB cancer cell line[J]. Cancer Res, 1999, 59(17): 4204-4207.
5Dumontet C, Fabianowska-Majewsda K, Mantincic D, et al, Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562[J]. Br J Haematol, 1999, 106(1):78-85.
6Davidson J D, Ma L, Flagella M, et al. An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines[J]. Cancer Res, 2004, 64(11): 3761-3766.
7Donk W A, Yu G, Perez L, ct al. Detection of a new substrate-derived radical during inactivation of ribonucleotide reductase from Escherichia coli by gemcitabine 5-diphosphate[J]. Biochemistry, 1998,37(18): 6419-6426.
8Rosell R, Danenberg K, Sanchez J J, et al. Ribonucleotide reductase MI (RRM1) mRNA expression and survival in advanced non-small-cell lung cancer patients treated with gemcitabine plus cisplatin [J].Lung Cancer, 2003, 41(Suppl 2): 0-43.
9Rosell R, Felip E, Taron M, et al. Gene expression as a predictive marker of outcome in stage ⅢB-ⅢA-ⅢB non-small-cell lung cancer after induction gemcitabinc-based chemotherapy followed by resectional surgery[J]. Clin Cancer Res, 2004, 10(Suppl): 4215-4219.
10Rosell R, Crino L, Danenberg K, et al. Targeted therapy in combination with gemcitabine in non-small cell lung cancer[J]. Semin Oncol,2003, 30(4 Suppl 10): 19-25.
